3 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow AFM13: new trials by email Literature Review of AFM13 trials Research Report on AFM13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas AFM13 - Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Completed | Ahmed Sawas | 18 | 2017-07-17 | 2023-07-20 |
| Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma AFM13, Pembrolizumab - Hodgkin Lymphoma | Phase 1 | Completed | Affimed GmbH | 30 | 2016-05-01 | 2019-05-16 |
Lymphoma, T-Cell (2) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Affimed GmbH (1) · Ahmed Sawas (1) · M.D. Anderson Cancer Center (1)
United States (3) · Spain (1)
Ahmed Sawas, MD (1) · Yago L Nieto (1)